Ossium Health, a therapeutics company harnessing stem cell science to improve treatment for patients with blood and immune diseases, announced the completion of its $63 million Series B funding round co-led by General Catalyst and Vivo Capital with participation from previous investors First Round Capital, Manta Ray Ventures, and XYZ Capital.

Ossium Health is a therapeutics company that leverages its unique deceased donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases.